These data not only demonstrate an additional mechanism by which Pten deficient prostate cancer cells can progress to CRPC but also has strong implications for therapies intended to directly target the ligand binding domain of the androgen receptor. This evidence concerns the gene PTEN and Familial prostate cancer.